We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-5.41%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$7.1B
AUM Growth
-$1.16B
Cap. Flow
-$291M
Cap. Flow %
-4.1%
Top 10 Hldgs %
41.94%
Holding
104
New
17
Increased
24
Reduced
34
Closed
18

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$151M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$136M
3
MDT icon
Medtronic
MDT
+$115M
4
DXCM icon
DexCom
DXCM
+$83.5M
5
LIVN icon
LivaNova
LIVN
+$79.9M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$149M
2
GILD icon
Gilead Sciences
GILD
+$133M
3
ONEM
1Life Healthcare
ONEM
+$129M
4
BEAM icon
Beam Therapeutics
BEAM
+$119M
5
SNY icon
Sanofi
SNY
+$96.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.86%
2 Financials 0.83%
3 Consumer Staples 0.3%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
1
Fate Therapeutics
FATE
$304M
$1.07B 15.05%
12,957,222
+327,485
+3% +$31.4M
ALLK
2
DELISTED
Allakos
ALLK
$278M 3.91%
2,419,418
-248,033
-9% -$31.3M
IGMS
3
DELISTED
IGM Biosciences
IGMS
$263M 3.7%
3,425,455
– –
ARGX icon
4
argenx
ARGX
$66.2B
$234M 3.3%
849,845
-68,462
-7% -$21.6M
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$209M 2.94%
21,114,114
+493,624
+2% +$7.64M
BEAM icon
6
Beam Therapeutics
BEAM
$3.15B
$203M 2.86%
2,532,523
-1,245,739
-33% -$119M
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$195M 2.75%
4,351,644
-86,324
-2% -$4.02M
NVTA
8
DELISTED
Invitae Corporation
NVTA
$185M 2.61%
4,852,163
-411,146
-8% -$18.7M
ADCT icon
9
ADC Therapeutics
ADCT
$143M
$178M 2.51%
7,308,418
+549,624
+8% +$15.9M
STTK icon
10
Shattuck Labs
STTK
$768M
$164M 2.31%
5,619,914
– –
MDVL
11
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$164M 2.31%
234,495
– –
OSH
12
DELISTED
Oak Street Health, Inc.
OSH
$159M 2.24%
2,930,411
+4,700
+0.2% +$261K
KRYS icon
13
Krystal Biotech
KRYS
$10.6B
$159M 2.24%
2,060,132
+385,096
+23% +$28M
JAZZ icon
14
Jazz Pharmaceuticals
JAZZ
$16.3B
$136M 1.92%
+829,159
New +$136M
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
$130M 1.83%
+937,045
New +$151M
PLRX icon
16
Pliant Therapeutics
PLRX
$71.2M
$126M 1.78%
3,207,193
-181,183
-5% -$5.88M
REPL icon
17
Replimune Group
REPL
$1.47B
$126M 1.77%
4,118,212
+124,813
+3% +$4.67M
MDT icon
18
Medtronic
MDT
$115B
$116M 1.63%
+979,108
New +$115M
SRRK icon
19
Scholar Rock
SRRK
$7.22B
$110M 1.55%
2,176,628
-719,961
-25% -$39.8M
NRIX icon
20
Nurix Therapeutics
NRIX
$2.79B
$103M 1.45%
3,314,117
+467,992
+16% +$17.7M
KYMR icon
21
Kymera Therapeutics
KYMR
$10B
$101M 1.42%
2,603,139
-117,350
-4% -$7.06M
ATRA icon
22
Atara Biotherapeutics
ATRA
$92.8M
$98.9M 1.39%
275,409
+886
+0.3% +$392K
STOK icon
23
Stoke Therapeutics
STOK
$2.1B
$98.8M 1.39%
2,544,062
-142,172
-5% -$8.09M
ZNTL icon
24
Zentalis Pharmaceuticals
ZNTL
$367M
$96.4M 1.36%
2,221,044
-195,362
-8% -$8.41M
ANNX icon
25
Annexon
ANNX
$995M
$96.3M 1.36%
3,458,830
+10,800
+0.3% +$297K
1
2 3 4 5

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2021 Portfolio in Review

As of Q1 2021, Redmile Group held 104 positions worth $7.1B, down 14% from $8.26B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group withdrew a net $291M in Q1 2021, closing 18 positions and reducing 34 holdings. Its most notable exit was AbbVie, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Redmile Group opened a new position in Seagen Inc. Common Stock worth $130M.

  • Redmile Group's largest Q1 2021 buy was Seagen Inc. Common Stock: 937,045 shares worth $130M.
  • Redmile Group added most to Fate Therapeutics in Q1 2021, an estimated $31.4M increase.
  • Redmile Group's biggest Q1 2021 reduction was 1Life Healthcare, cutting an estimated $129M.
  • Redmile Group fully exited AbbVie in Q1 2021, selling an estimated $149M.
  • Redmile Group's ten largest holdings make up 42% of its $7.1B portfolio in Q1 2021.
  • Redmile Group opened 17 new positions and closed 18 in Q1 2021.
  • Redmile Group's portfolio value fell 14% quarter-over-quarter to $7.1B.

Based on Redmile Group's 13F filing for Q1 2021, filed 17 May 2021.